TekCapital Regulatory News (TEK)

Dissemination of a Regulatory Announcement that contains inside information according to REGULATION (EU) No 596/2014 (MAR)

Tekcapital plc

("Tekcapital")

Private Placement for Belluscura Ltd

Follow-on funding round raises US$675,000

Tekcapital plc (AIM: TEK), an international provider of technology and intellectual property services, is pleased to announce that Belluscura Ltd ("Belluscura") has concluded an oversubscribed private placement to raise approximately US$675,000 ("Private Placement").

The Company announced on 17 June 2016 that it planned to extend its fundraising round and this Private Placement has been concluded on similar terms, giving Belluscura a post-money valuation of US$5,250,000. Tekcapital now owns approximately 65% of the share capital of Belluscura.

In line with the previous fundraising (announced on 17 June 2016) the proceeds of the Private Placement are intended to be applied as follows:

- regulatory, safety and quality expenses for medical products, including CE Marking and certification for European sales;

- implementing product manufacturing and acquiring initial stock;

- acquisition of additional medical products; and

- working capital purposes.

Investors in the Private Placement include Nigel Wray and his family and as they hold more than 10 per cent. of Tekcapital's and Belluscura's ordinary shares, their participation of US$100,000 in the Private Placement is deemed to be a related party transaction pursuant to rule 13 of the AIM Rules for Companies. Accordingly, the directors of Tekcapital consider, having consulted with the Company's nominated adviser, Allenby Capital, that the terms of the subscription with Nigel Wray are fair and reasonable insofar as Tekcapital's shareholders are concerned.

Commenting on the private placement, Dr. Clifford M. Gross, Executive Chairman of Tekcapital, said: "We are very pleased to announce the second tranche of the private placement into Belluscura. Belluscura's mission is to provide premium, proprietary medical devices at affordable prices."

For further information, please contact:

Tekcapital plc - The World's Largest University Network for Open Innovation

Tekcapital helps clients profit from new, university-developed intellectual properties. With our proprietary discovery search engine, linked to 4,000+ universities in 160 countries, coupled with expert scientific review, we provide a turn-key service to make it easy for clients to find and acquire the IP, analytics and technology transfer professionals they need to create a competitive advantage. Tekcapital plc is listed on the AIM market of the London Stock Exchange (AIM: symbol TEK) and is headquartered in Oxford, in the UK. For more information, please visit www.tekcapital.com

Background to Belluscura

Belluscura (www.belluscura.com) was established in the UK in December 2015 to provide premium proprietary medical devices at affordable prices, to address part of the global unmet need for inexpensive, superior medical devices. Belluscura will seek to achieve this goal by acquiring, then manufacturing and selling, proprietary medical devices deemed to be non-core or undervalued by leading medical device companies on an on-going basis.

In line with this strategy, as previously announced by Tekcapital on 13 April 2016 and 15 September 2016, Belluscura acquired the exclusive licenses to manufacture and sell four medical products from Stryker Corporation, a leading medical technology company. The devices are:

1. SlydeTM, a lightweight stretcher designed for use in emergency evacuations of multi-storey structures;

2. Passport®, a surgical trocar designed as a camera port for use in laparoscopy (keyhole surgery);

3. SNAP II, a level of consciousness monitor for use during surgical procedures requiring general anesthesia; and

4. Wire CaddyTM, an innovative wire management system that provides lubrication and organization during multi-wire, multi-exchange operating room cases such as cardiology interventions, uterine fibroid embolizations and tibial angioplasties.

These four devices are protected by a comprehensive intellectual property portfolio of 19 issued and pending patents and industrial designs. They have received US 510(k) regulatory clearance where necessary and have already recorded commercial sales revenue for Stryker. In addition, Passport has been awarded a CE Marking for distribution in the EU.

Belluscura has begun manufacturing and selling the Slyde products in the US and plans to subcontract the manufacturing of the other products with the intention to sell them through external sales channels at affordable prices globally with a focus on the US, Europe, India and China.

In addition, Belluscura is evaluating a patented technology relating to the non-invasive measurement of glucose in saliva for the treatment of diabetes - Saliva Glucose Measurement Technology ("SGMT"). Tekcapital novated to Belluscura its worldwide exclusive licenses to a patent and related patent application for SGMT for companion animals (and humans). This technology is licensed from and was developed by Arizona State University. Further details on these licences were announced by Tekcapital on 2 April 2015 and 14 March 2016.

Belluscura plans to acquire additional developed medical products which have already achieved regulatory clearance or approval, or require limited additional regulatory clearance or approval, and are deemed to be non-core by leading medical device manufacturers. Furthermore, Belluscura will also endeavour to identify and acquire undervalued proprietary technologies in the medical space that require limited investment to reach commercialisation.

Belluscura has an experienced executive management team, independent of Tekcapital, with significant expertise in the medical devices industry that covers a broad spectrum of disciplines in business, law, medicine and technology.